Abstract 340P
Background
The optimal follow-up strategy for the detection of relapse in patients with diffuse large B-cell lymphoma (DLBCL) has not been clarified. In this report, we assess the role of laboratory tests and CT for surveillance and investigate the risk factors for recurrence.
Methods
We reviewed the clinical records of patients who achieved CR by PET-CT after received R-CHOP like regimen in our hospital for DLBCL between February 2008 and February 2022. Clinical evaluation post treatment was done every 3-6 months in the first 2 years, and every 6–12 years in the 3 coming years.
Results
A total of 324 patients were eligible for inclusion in this study. The median duration of follow-up for surviving patients was 4.3 years. The cumulative incidence of relapse without death at 2 and 5 years was 13.3% and 21.6%. Overall, 1453 CT scans were carried out through surveillance. The total of 64 patients relapsed within the observation period. Of these, 19 patients were detected to have recurrence on surveillance CT scans. On univariate analysis, ABC-type, extranodal (EN) stites > 1 at diagnosi, and relative dose intensity (RDI) < 90% were risk factors for recurrence. On Fine-Gray regression analysis, ABC-type (HR 2.1, 95% confidence interval [95% CI] 1.1-3.7. p=0.018) and EN sites > 1 at diagnosis (HR 1.8, 95% CI 1.1-3.6. p=0.031) were independent risk factors for recurrence. The area under the curve (AUC) of the receiver operating characteristic (ROC) curve of the surveillance value of soluble interleukin-2 (sIL-2R) (HR 0.81, 95% CI 0.72–0.90) was significantly larger than lactate dehydrogenase (LDH) (0.65, 95% CI 0.55–0.75. p=0.024). While in the normal pretreatment sIL-2R group, the AUC of the ROC curve of sIL2R was small (0.57), however, in the high pretreatment sIL-2R group, the AUC of the ROC curve of sIL2-R (0.83, 95% CI 0.74-0.91) was high. We defined the best cutoff value of the sIL2-R as 607.5 using a ROC curve in the high pretreatment sIL-2R group (Sensitivity 0.63. Specificity 0.88).
Conclusions
Routine surveillance CT scans were of limited value in detecting asymptomatic relapse. ABC-type and EN sites were independent risk factors for recurrence. The measurement of sIL-2R might be useful for surveillance.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
193P - Impact of coronavirus disease 2019 on patients with unresectable hepatocellular carcinoma treated with atezolizumab/bevacizumab
Presenter: Hongjae Chon
Session: Poster Display
Resources:
Abstract
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract